DC
OREX

Deere & Company’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Deere & Company’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-5,953
Closed -$295K – 1155
2015
Q2 		$295K Buy
5,953
+2,830
+91% +$169K 0.02% 773
2015
Q1 		$245K Hold
3,123
– – 0.01% 806
2014
Q4 		$189K Buy
+3,123
New +$157K 0.01% 911

Other funds holding OREX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deere & Company's OREX Position: Q3 2015 in Review

Deere & Company sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2015, closing a stake of 5,953 shares — an estimated $295K sold.

Deere & Company first reported a position in OREX in Q4 2014 and held it in 3 quarters. The position peaked at $295K in Q2 2015. 132 funds tracked by Wall St. Rank hold OREX as of Q3 2015.

  • Deere & Company reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Deere & Company sold 5,953 Orexigen Therapeutics, Inc. shares in Q3 2015, an estimated $295K.
  • Deere & Company first reported a position in Orexigen Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
  • Deere & Company's Orexigen Therapeutics, Inc. position peaked at $295K in Q2 2015.
  • 132 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2015.

Based on Deere & Company's 13F filing for Q3 2015, filed 12 Nov 2015.